FormFactor Inc. FormFactor Inc. Common Stock vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $141.39 (market cap $10.71B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 5.5× FormFactor Inc. FormFactor Inc. Common Stock's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while FormFactor Inc. FormFactor Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 0 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| FORM | TAK | |
|---|---|---|
Market Cap | $10.71B | $58.74B |
Volume | 1,680,425 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $159.93 | $19.05 |
52-Week Low | $38.14 | $13.23 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.40B | $86.65B |
Dividend Yield | — | 3.33% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →